Ujjal Didar Singh Sekhon/LinkedIn
Jul 28, 2026, 08:28
Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
Ujjal Didar Singh Sekhon, Director of Research Development at Haima Therapeutics, shared a post on LinkedIn:
“ISTH 2026 was a privilege to be part of: pathbreaking research, illuminating conversations, and a dose of Paris on top.
I was honored to present our work advancing SynthoPlate through models of P2Y12 blockade.
A huge thanks to the Haima team behind this milestone, and to the colleagues who came by with questions and suggestions that will sharpen what comes next.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios AndreadisÖ‰ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI